Concepta (AIM: CPT), formerly named Concepta Diagnostics Ltd, is a healthcare company operating in the area of fertility and, more specifically, in the global market segment of unexplained infertility. Concepta's market-ready products target the personalised mobile health market.
Its product range recently achieved product registration in one of its largest target markets, China, where the abolition of China's one-child policy is expected to drive significant demand for a cost-effective at-home fertility monitoring system as parents seek to have additional children. Concepta's product range provides reliable data to women for a variety of fertility applications, using proprietary disposable test strips and devices linked to a mobile app which captures levels of key fertility hormones in urine and builds an accurate and easy-to-understand "digital diary".
Concepta originally received investment via the Group's third party funds and early stage capital through Enterprise Ventures, which was acquired by the Group in March 2016.
Concepta PLC, formerly named Concepta Diagnostics Ltd, was admitted to AIM on 26 July 2016. The enlarged ordinary share capital of Concepta, comprising 109,160,573 new ordinary shares, was admitted to trading by way of a reverse takeover of Frontier Resources International plc. Mercia invested £1.0million as part of the placing and held approximately 18.32% of the total share capital following the transaction.
To read the full RNS announcement, click here.